Clinical Trial

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-09
notable Primary completion pushed: 2031-12 -> 2032-12 2026-07-09
minor Completion pushed: 2031-12 -> 2032-12 2026-07-09
Trial Details
NCT Number NCT07447557
Lead Sponsor Elpida Therapeutics SPC
Conditions Charcot-Marie-Tooth Disease Type 4J
Enrollment 8 participants
Start Date 2026-07
Primary Completion 2032-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-08